None listed
Conditions
Brief summary
This study aims to evaluate whether a new type of brain imaging called an Amyloid PET/CT scan can improve the diagnosis of Alzheimer’s disease in patients where previous tests have been inconclusive. The hypothesis is that this scan will provide additional diagnostic information, helping doctors make a clearer diagnosis or exclude Alzheimer’s disease. Fifty patients with unclear results from an earlier scan (FDG PET/CT) will undergo the Amyloid PET/CT scan. The results will be reviewed by a team of specialists to determine if the new imaging adds value to the diagnosis.
Interventions
This study is a prospective, non-randomised, non-blinded feasibility assessment aimed at determining whether a new type of brain scan called an Amyloid (18F-Florbetaben) Positron Emission Tomography/Computed Tomography (Amyloid PET/CT) scan can provide additional benefits in diagnosing Alzheimer’s disease. This scan may be particularly useful in cases where other tests, including clinical assessments and the commonly used Fluorodeoxyglucose (FDG) PET/CT scan, have not provided clear diagnostic r
This study is a prospective, non-randomised, non-blinded feasibility assessment aimed at determining whether a new type of brain scan called an Amyloid (18F-Florbetaben) Positron Emission Tomography/Computed Tomography (Amyloid PET/CT) scan can provide additional benefits in diagnosing Alzheimer’s disease. This scan may be particularly useful in cases where other tests, including clinical assessments and the commonly used Fluorodeoxyglucose (FDG) PET/CT scan, have not provided clear diagnostic results. Participation in this study involves one imaging scan outside of standard care: the Amyloid PET/CT scan. The Amyloid PET/CT scan will be performed at I-MED Radiology, The Wesley Hospital (Brisbane), and interpreted by a nuclear medicine radiologist involved in this study. The total time required for the scan process is approximately 3 hours. Each patient will receive 300 MBq (+/-10%) of the Florbetaben tracer via intravenous cannulation, administered 90 minutes before the PET/CT scan. The scan itself will take approximately 20 minutes to complete.
Sponsors
I-MED Radiology Network
Study design
Allocation
Non-randomised trial
Primary purpose
Diagnosis
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion criteria: • Aged 18 years or older • Have undergone FDG PET/CT brain imaging as part of routine Alzheimer's disease evaluation and received equivocal results • Deemed eligible by the Wesley NeuroPET Multidisciplinary team (MDT) for study participation • Willing and physically able to undergo an additional Amyloid PET/CT scan as per study protocol • Has adequate renal function (eGFR >30 mL/min/1.73 m²) • Willing and able to provide informed consent (or consent may be provided through a surrogate) to participate in the study
Exclusion criteria
Exclusion criteria: • Aged younger than 18 years • Have undergone FDG PET/CT brain imaging as part of routine Alzheimer's disease evaluation and received conclusive results • Known allergies or contraindications to the components used in PET imaging. • Significant medical conditions or comorbidities that could interfere with study participation or pose a risk during PET scanning • History of other neurological disorders or conditions that may confound the interpretation of amyloid PET/CT results • Current participation in other clinical trials involving investigational drugs or interventions that could affect study outcomes • Inability to comply with study procedures due to logistical or other reasons • Pregnant or breastfeeding
Outcome results
None listed